Open this publication in new window or tab >>Show others...
2018 (English)In: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 14, p. P759-P760, article id 7Article in journal (Other academic) Published
Abstract [en]
The development of novel therapies for Alzheimer’s Disease (AD) is constrained by the lack of available methods for preclinical diagnosis, despite extensive research on biomarker identification. Here, we present an update of progress from EMPIR NeuroMET, a project combining diverse expertise from five National Measurement Institutes (NMIs), with clinicians and academics, to overcome limitations in measurement methods in neurodegenerative disease diagnosis and treatment.
National Category
Neurosciences
Identifiers
urn:nbn:se:ri:diva-36099 (URN)10.1016/j.jalz.2018.06.920 (DOI)
Projects
EMPIR 15HLT04 NeuroMet
Funder
EU, Horizon 2020, EMPIR 15HLT04
2018-11-092018-11-092018-11-12Bibliographically approved